Immuno-Oncology Webinar: Different Routes To The Same Destination
This article was originally published in Scrip
Bristol-Myers Squibb has shot out of the starting gate in the great immuno-oncology race, with Merck & Co hot on its tail. Frenzied deal making and exponential growth in the number of investigational products and clinical trials taking place suggest, however, that there is ample room for a range of players in this market.
You may also be interested in...
A recent segment of CBS News “60 Minutes” discussing potential health benefits from probiotics was highly criticized by groups including the Consumer Healthcare Products Association, the Council for Responsible Nutrition, the Natural Products Association and the International Probiotics Association.
After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.
Samsung Bioepis is the latest company to stare down a lawsuit from Genentech over Avastin patents in the US. The Korean firm is aiming to be amongst the early biosimilar movers, after the market formed a year ago.